LivingGLP1
Study S001685

Efficacy of a Glucagon-like-peptide-1 Agonist and Restrictive vs. Liberal Oxygen Supply in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement - a 2-by-2 Factorial Designed, Randomized Clinical Study

ClinicalTrials.gov record

Registration

Registration
NCT02673931
Acronym
GLORIOUS
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
QUADRUPLE
Status
UNKNOWN
Enrollment
1400
Start
2016-02
Primary completion
2024-09
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Conditions
Coronary Disease; Shock, Cardiogenic; Renal Failure; Stroke; Brain Injury; Aortic Valve Disease
Interventions
DRUG:Byetta (Lilly, Exenatide); DRUG:Conoxia (AGA, oxygen); DRUG:20% Human Albumin
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Time in days to the first occurring of the following co-primary end-points throughout the follow-up period [Minimum 12 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0013532Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.
Kjaergaard J, Circulation. Cardiovascular interventions
2025Randomized trialPMID 40265262DOIcites ClinicalTrials.gov:NCT02673931; registry reference DERIVED:40265262
R0015605Efficacy of a glucagon-like peptide-1 agonist and restrictive versus liberal oxygen supply in patients undergoing coronary artery bypass grafting or aortic valve replacement: study protocol for a 2-by-2 factorial designed, randomised clinical trial.
Wiberg S, BMJ open
2021ProtocolPMID 34740932DOIcites ClinicalTrials.gov:NCT02673931; registry reference DERIVED:34740932